Alcobra Ltd., an emerging biopharmaceutical company primarily focused on the development and commercialization of a proprietary drug, MG01CI, announced the pricing of initial public offering of 3.125 million ordinary shares at $8.00 per share, below its expected price range. The offering is expected to close on May 28, 2013.
In the amended F-1filing with the SEC, the company had expected the pricing between $10.00 and $12.00 per share.
The company, which is developing a treatment for attention deficit hyperactivity disorder, expects gross proceeds from the initial public offering to be $25 million before underwriting discounts and commissions and other offering expenses.
Alcobra, which was founded in 2008, has granted the representative of the underwriters a 45-day option to purchase up to 458,125 additional ordinary shares from Alcobra to cover over-allotments.
Israel-based company's ordinary shares are scheduled to begin trading on The NASDAQ Capital Market on May 22, 2013 under the symbol "ADHD."
Aegis Capital Corp. is acting as sole book-running manager for the offering. Sunrise Securities Corp. and Feltl & Company, Inc are acting as co-managers for the offering.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.